EnWave Announces Radiant Energy Vacuum Technology Testing Agreement With Tier 1 Pharmaceutical Company for Monoclonal

 EnWave Announces Radiant Energy Vacuum Technology Testing Agreement With Tier 1  Pharmaceutical Company  for Monoclonal Antibodies  NEWS RELEASE TRANSMITTED BY Marketwired  FOR: EnWave Corporation  TSX VENTURE SYMBOL:  ENW FRANKFURT SYMBOL:  E4U  MARCH 10, 2014  EnWave Announces Radiant Energy Vacuum Technology Testing Agreement With Tier 1 Pharmaceutical Company  for Monoclonal Antibodies  VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 10, 2014) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the "Company") announced today that it has signed a Testing Agreement (the "Agreement") with a Tier 1 pharmaceutical company (the "Tier 1") that is in the top five globally for Research and Development spending. The Agreement allows the Tier 1 to exclusively test EnWave's Radiant Energy Vacuum ("REV(TM)") technology for the dehydration of monoclonal antibodies ("mAbs"). The testing period is expected to begin in late March 2014.   Prior to signing this Agreement, EnWave received positive results in 2011 from a 12 month study comparing the Company's REV(R) dehydration technology against the standard industrial drying method, freeze drying, in the dehydration of pure samples of a FITC-conjugated and unconjugated animal-derived mAbs. The results showed that the drying methods were equivalent in terms of the structural changes incurred by the antibodies both immediately post-dehydration, and over the course of the 12 month shelf-life period, but that the samples dried using REV(R) were dehydrated in considerably less time than required for freeze drying. This was a significant test result as mAbs are much more sensitive and therefore prone to degradation during dehydration.  mAbs are produced by a single clone of cells grown in culture, that is both pure and specific and is capable of proliferating indefinitely to produce unlimited quantities of identical antibodies. Beyond basic research, in recent years, therapeutic mAbs have become an increasingly important component of pharmacotherapy and have made a significant impact on the drug discovery and development process.   Although antibodies are not considered live organisms, dehydration can cause them to become inactive, and therefore ineffective for use in pharmaceutical and other products, by changing or "denaturing" their outer protein structure.  "We have proven that REV(TM) technology can efficiently dehydrate monoclonal antibodies while preserving their efficacy," stated Dr. Tim Durance, Chairman & Co-CEO of EnWave Corporation. "This Agreement will provide the opportunity to exhibit the value proposition to this leading Tier 1 pharmaceutical partner."  About EnWave   EnWave Corporation is a Vancouver-based industrial technology company developing commercial applications for its proprietary Radiant Energy Vacuum (REV(TM)) dehydration technology. EnWave aims to sign royalty-bearing commercial licenses with leading food and pharmaceutical companies for the use of its revolutionary technology. Thus far the Company has signed commercial licenses with Bonduelle, a global leader in the production of vegetables, for the processing of dehydrofrozen vegetables; Hormel Foods Corporation, a major processed meat manufacturer, for the production of healthy dried meat products; Milne Fruit Product, EnWave's first major licensee, for the production of several dehydrated fruit and vegetable products in the whole, fragmented and powdered form; a leading North American enzyme company, to dehydrate a series of food-related enzymes for their Tier 1 clients; and Napa Mountain Spice Company, to dry high-quality California bay leaves. In addition to these licenses, EnWave has formed a Limited Liability Partnership with Lucid Capital Management to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese(R) brand.   Also, EnWave has entered into a wide range of research and collaboration agreements with an expanding list of multinational companies, including Nestle, Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Cherry Central, Sun-Maid Growers, Gay Lea Foods, R.J. Reynolds and Merck. EnWave is introducing REV(TM) as a new dehydration standard in the food and biological material sectors: potentially faster and cheaper than freeze drying, with better end product quality than air drying or spray drying.  EnWave currently has six REV(TM) platforms: commercial-scale nutraREV(R) and MIVAP(R) are used in the food industry to dry fruits, vegetables, meat, herbs and seafood quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour. The Company is also developing powderREV(R) for bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes; quantaREV(TM) for continuous, high-volume low-temperature drying of pastes, gels, liquids, or particulates; and bioREV(TM) and freezeREV(TM) as new methods to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.   EnWave Corporation  Dr. Tim Durance, Chairman & Co-CEO   Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  -30- FOR FURTHER INFORMATION PLEASE CONTACT:  EnWave Corporation Mr. John McNicol President & Co-CEO (604) 601-8524 john.mcnicol@enwave.net or EnWave Corporation Mr. Brent Charleton Vice President, Corporate Affairs (778) 378-9616 bcharleton@enwave.net  INDUSTRY:  Medical and Healthcare - Alternative, Medical and Healthcare - Dentistry, Medical and Healthcare - Mental Health, Medical and Healthcare - Nursing, Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech - Drugs  SUBJECT:  BFC 
Press spacebar to pause and continue. Press esc to stop.